Cognitive Fusion Prostate Biopsy With Biparametric Magnetic Resonance in the Detection of Prostate Cancer
Study Details
Study Description
Brief Summary
The goal of this prospective observational study is to evaluate the diagnostic precision of the Biparametric Magnetic Resonance Imaging (bpMRI) in the detection of clinically significant prostate cancer in patients with biochemical suspicion of prostate cancer (Prostate Specific Antigen in blood test > 4 ng/mL) with a normal digital rectal examination and without a biopsy previous to the MRI. Secondary aims are:
-
Determine the validity as a diagnostic test of the first directed transrectal prostatic biopsy (cognitive fusion) versus systematic biopsy of 12 cylinders in patients with suspicious lesions in the bpMRI.
-
Develop a predictive nomogram that permits the reduction of the number of prostatic biopsies performed to patients with a low suspicion of prostate cancer in the bpMRI.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
In Spain, prostate cancer (PCa) is the most common cancer independently from gender and the third cause of death in man, below lung and colorectal cancer. Incidence and mortality increase progressively as age increases, hence, due to an older population, this is an outstanding sociosanitary concern.
PCa generally is asymptomatic, diagnosis is based on prostate biopsy in man with an elevated Prostate Specific Antigen (PSA) in blood test and/or a pathologic digital rectal examination.
Multiparametric Magnetic Resonance Imaging (MRImp) plays an important role in the diagnosis. It allows the visualization of the tumor, it values its agresitivity (PI-RADS v2 scale), and permits a directed biopsy to the suspicious lesion.
This tecnique is expensive and very uncomfortable for the patient due its duration (40 minutes) and because it uses intravenous (iv) contrast. Due to these reasons, it is difficult to assume by the sanitary system to perform this technique to every patient with PCa suspicion.
Biparametric MRI emerges as an alternative with a new protocol, performed with less image sequences (T2 and diffusion), cheaper, lasting less (just 15 minutes), and without the administration of iv contrast. Thus, this technique is more assumable by a public sanitary system.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| MRI + PI-RADS 3-5 |
Diagnostic Test: fusion cognitive prostate biopsy
A standard transrectal prostatic biopsy will be performed to both groups. To the group with suspicious lesions in the MRI (PI-RADS 3-5), an added directed cognitive fusion biopsy will be performed.
Other Names:
|
| MRI - PI-RADS 1-2 |
Outcome Measures
Primary Outcome Measures
- Diagnostic precision of Biparametric Magnetic Resonance Imaging. [1 hour]
evaluate the diagnostic precision of the Biparametric Magnetic Resonance Imaging (bpMRI) in the detection of clinically significant prostate cancer in patients with biochemical suspicion of prostate cancer (Prostate Specific Antigen in blood test > 4 ng/mL) with a normal digital rectal examination and without a biopsy previous to the MRI
Secondary Outcome Measures
- Validity of first directed transrectal prostatic biopsy [1 hour]
Determine the validity as a diagnostic test of the first directed transrectal prostatic biopsy (cognitive fusion) versus systematic biopsy of 12 cylinders in patients with suspicious lesions in the bpMRI.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Male patients between 18 and 80 years
-
BpMRI performed in a 3 months period before the prostatic biopsy
-
First transrectal prostatic biopsy
-
PSA > 4 ng/mL and < 20 ng/mL
-
Patients acceptance to participate in the study signing a written specific informed consent
Exclusion Criteria:
-
Not having all the inclusion criteria described
-
Suspicious digital rectal examination of prostate cancer
-
Previous urinary tract infection in the last six months, acute urinary retention or being a chronic carrier of bladder catheter
-
Previous prostatic surgery in any of its variants
-
Concomitant treatment with LH-RH analogue, antiandrogens or 5-alfa-reductase inhibitors
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Universidad Miguel Hernández de Elche | Alicante | Spain | 03550 |
Sponsors and Collaborators
- José Joaquín Mira
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- RM FAST